BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=69567&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=69416&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in BioVie Lawsuit – BIVI

LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=69316&wire=1 or contact Joseph E. Levi, Esq.

BioVie Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIVI

LOS ANGELES, CA / ACCESSWIRE / March 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 4, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the "Class Period"), of the important March 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVI

BioVie (NASDAQ: BIVI ) stock is falling on Monday after the biopharmaceutical company revealed details for a public stock offering. BioVie has priced its shares at $1 each in the public offering.

Why Is BioVie (BIVI) Stock Down 41% Today?

NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=68846&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- Carson City, Nevada – March 1, 2024 – BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in a best efforts public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.

BioVie Inc. Announces Proposed Public Offering of Common Stoc

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in a best efforts public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.

BioVie Inc. Announces Proposed Public Offering of Common Stock

BioVie (NASDAQ: BIVI ) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107. NE3107 is BioVie's inhibitor of inflammatory activation of ERK and NFkB.

Why Is BioVie (BIVI) Stock Up 100% Today?

BioVie Inc (NASDAQ:BIVI) shares surged 130% in early trade on Friday after the company revealed that its lead asset NE3107 has demonstrated the potential to improve motor and non-motor symptoms in patients with Parkinson's disease in a mid-stage clinical trial.  The company said data from its Phase 2a trial showed Parkinson's Disease patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control, while patients in the placebo arm worsened.

BioVie shares surge on lead asset NE3107's potential to improve Parkinson's Disease symptoms

Data from Phase 2a trial in Parkinson's Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened

BioVie's NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for Alzheimer's Patients in Data to be Presented at the International Conference on Alzheime

NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie

NEW YORK, NY / ACCESSWIRE / February 27, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=68345&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 – BIVI

NEW YORK, NY / ACCESSWIRE / February 26, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=68215&wire=1 or contact Joseph E. Levi, Esq.

BioVie Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – BIVI

NEW YORK , Feb. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioVie Inc.. Shareholders who purchased shares of BIVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIVI

NEW YORK , Feb. 23, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the "Class Period"), of the important March 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A RANKED AND LEADING FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVI

NEW YORK, NY / ACCESSWIRE / February 22, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=67720&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of BioVie Inc.(BIVI) of a Class Action Lawsuit and an Upcoming Deadline

If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BIVI.

BIOVIE SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options

NEW YORK, NY / ACCESSWIRE / February 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=67441&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

PHILADELPHIA , Feb. 19, 2024 /PRNewswire/ -- Berger Montague announces that a class action lawsuit was filed in the U.S. District Court for the District of Nevada on behalf of those who acquired BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) securities. If you suffered losses as a result of your investment in BioVie (NASDAQ: BIVI) and would like to learn about a potential recovery, CLICK HERE.

NASDAQ: BIVI INVESTOR ALERT: Berger Montague Advises BioVie Inc. (NASDAQ: BIVI) Investors of March 19, 2024 Deadline

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the "Class Period"), of the important March 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING NATIONAL FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIVI

NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

News for BioVie Inc Stock (BIVI)